Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
Background Immunotherapy has considerably changed the treatment of lung cancer. As immunotherapy has a special mechanism of action, the disease remission that it can induce is unique. Recently, Immune Response Evaluation Criteria in Solid Tumors (iRECIST), which focus on assessing the apparent curat...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley
2019-04-01
|
| coleção: | Thoracic Cancer |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1111/1759-7714.13010 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|